Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Shares Lagging The Market But So Is The Business
Feb 13
Have your own idea? Try our Stock Screener
Chinese (SSE) Pharma Industry Analysis
UpdatedFeb 15, 2025
DataAggregated Company Financials
Companies219
- 7D0.8%
- 3M-5.2%
- 1Y5.1%
- YTD0.7%
The Pharma is pretty flat in the last 7 days, but Shanghai Fosun Pharmaceutical (Group) has stood out, gaining 3.4%. As for the the longer term, the industry is up 5.1% over the past 12 months. As for the next few years, earnings are expected to grow by 19% per annum.
Industry Valuation and Performance
Has the Chinese Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 16 Feb 2025 | CN¥2.5t | CN¥800.2b | CN¥75.6b | 28.6x | 33.4x | 3.2x |
| Tue, 14 Jan 2025 | CN¥2.4t | CN¥788.6b | CN¥75.1b | 26.5x | 32x | 3x |
| Thu, 12 Dec 2024 | CN¥2.7t | CN¥799.8b | CN¥75.6b | 32.6x | 36.2x | 3.4x |
| Sat, 09 Nov 2024 | CN¥2.8t | CN¥799.5b | CN¥75.5b | 30.9x | 36.7x | 3.5x |
| Mon, 07 Oct 2024 | CN¥2.7t | CN¥798.6b | CN¥76.3b | 29.7x | 36x | 3.4x |
| Wed, 04 Sep 2024 | CN¥2.3t | CN¥798.0b | CN¥76.2b | 26.4x | 30.3x | 2.9x |
| Fri, 02 Aug 2024 | CN¥2.3t | CN¥805.3b | CN¥76.4b | 27.2x | 30.7x | 2.9x |
| Sun, 30 Jun 2024 | CN¥2.3t | CN¥805.5b | CN¥74.6b | 27.4x | 31.5x | 2.9x |
| Tue, 28 May 2024 | CN¥2.7t | CN¥821.6b | CN¥77.6b | 29.7x | 34.5x | 3.3x |
| Thu, 25 Apr 2024 | CN¥2.6t | CN¥830.0b | CN¥79.9b | 28.4x | 32.3x | 3.1x |
| Sat, 23 Mar 2024 | CN¥2.6t | CN¥833.2b | CN¥81.1b | 27.9x | 32.5x | 3.2x |
| Mon, 19 Feb 2024 | CN¥2.5t | CN¥831.9b | CN¥81.0b | 25x | 30.3x | 2.9x |
| Wed, 17 Jan 2024 | CN¥2.7t | CN¥830.9b | CN¥79.7b | 29.8x | 33.6x | 3.2x |
| Fri, 15 Dec 2023 | CN¥2.9t | CN¥827.7b | CN¥79.7b | 31.3x | 36.6x | 3.5x |
| Sun, 12 Nov 2023 | CN¥2.8t | CN¥820.6b | CN¥78.7b | 31.3x | 35.9x | 3.4x |
| Tue, 10 Oct 2023 | CN¥2.8t | CN¥824.9b | CN¥78.6b | 31.6x | 35.7x | 3.4x |
| Thu, 07 Sep 2023 | CN¥2.6t | CN¥824.5b | CN¥78.5b | 30.7x | 33.3x | 3.2x |
| Sat, 05 Aug 2023 | CN¥2.7t | CN¥812.0b | CN¥77.2b | 31.4x | 35.3x | 3.4x |
| Mon, 03 Jul 2023 | CN¥2.8t | CN¥809.7b | CN¥76.5b | 32.6x | 37.1x | 3.5x |
| Wed, 31 May 2023 | CN¥3.0t | CN¥809.4b | CN¥76.3b | 34.9x | 39.2x | 3.7x |
| Fri, 28 Apr 2023 | CN¥3.0t | CN¥809.0b | CN¥92.2b | 34.7x | 32.5x | 3.7x |
| Sun, 26 Mar 2023 | CN¥2.8t | CN¥792.0b | CN¥87.2b | 35.2x | 32.4x | 3.6x |
| Tue, 21 Feb 2023 | CN¥3.0t | CN¥774.5b | CN¥83.0b | 37.7x | 35.9x | 3.8x |
| Thu, 19 Jan 2023 | CN¥2.9t | CN¥769.8b | CN¥82.8b | 34.6x | 34.5x | 3.7x |
| Sat, 17 Dec 2022 | CN¥2.9t | CN¥767.8b | CN¥81.9b | 38.9x | 35.5x | 3.8x |
| Mon, 14 Nov 2022 | CN¥2.7t | CN¥767.0b | CN¥81.7b | 36.2x | 33.4x | 3.6x |
| Wed, 12 Oct 2022 | CN¥2.4t | CN¥761.1b | CN¥79.6b | 29.9x | 29.5x | 3.1x |
| Fri, 09 Sep 2022 | CN¥2.5t | CN¥760.0b | CN¥79.3b | 31.9x | 31.8x | 3.3x |
| Sun, 07 Aug 2022 | CN¥2.7t | CN¥755.1b | CN¥81.9b | 30.8x | 32.5x | 3.5x |
| Tue, 05 Jul 2022 | CN¥2.9t | CN¥742.3b | CN¥80.3b | 33.2x | 36.1x | 3.9x |
| Thu, 02 Jun 2022 | CN¥2.6t | CN¥740.1b | CN¥82.0b | 31.8x | 31.1x | 3.4x |
| Sat, 30 Apr 2022 | CN¥2.4t | CN¥735.7b | CN¥78.3b | 29.2x | 31.2x | 3.3x |
| Mon, 28 Mar 2022 | CN¥2.9t | CN¥729.0b | CN¥77.3b | 34.7x | 37.2x | 3.9x |
| Wed, 23 Feb 2022 | CN¥2.8t | CN¥724.2b | CN¥74.6b | 32.3x | 37.5x | 3.9x |
Price to Earnings Ratio
37.5x
Current Industry PE
- Investors are relatively neutral on the Chinese Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 33.9x.
- The industry is trading close to its 3-year average PS ratio of 3.4x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
- Meanwhile revenues for these companies have grown 3.4% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 1.46% | |
| Healthcare | 2.76% | |
| Pharma | 0.80% | |
| Pharma | 0.80% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 600196 Shanghai Fosun Pharmaceutical (Group) | CN¥25.42 | 3.4% +CN¥2.2b | 6.1% | PE32x | |
| 600436 Zhangzhou Pientzehuang Pharmaceutical | CN¥209.65 | 1.8% +CN¥2.2b | -2.9% | PE41.1x | |
| 603707 Nanjing King-Friend Biochemical PharmaceuticalLtd | CN¥14.45 | 6.3% +CN¥1.4b | 3.9% | PS6x | |
| 600422 KPC PharmaceuticalsInc | CN¥18.10 | 11.0% +CN¥1.4b | -10.6% | PE30.7x | |
| 600276 Jiangsu Hengrui Medicine | CN¥45.50 | 0.5% +CN¥1.3b | 8.7% | PE53.1x |
